The objective of this educational initiative is to provide evidence-based information on the latest developments in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), including updates on EGFR tyrosine kinase inhibitors (TKIs), as well as the importance of EGFR mutation testing, including molecular profiling using circulating tumor DNA (ctDNA) for tailoring therapy and improving patient outcomes. Practical strategies for using some of the newer therapies as well as companion diagnostic testing and technologies to detect EGFR mutations from ctDNA in advanced NSCLC patients will be incorporated into this Grand Rounds series. This initiative is targeted toward clinicians involved in the care of patients with advanced lung cancer, specifically physicians, nurses, and pharmacists specializing/practicing in academic or community hospitals.